Skip to content
Open access

Anti-trypanosomal activity and target validation of the M17 leucyl-aminopeptidase inhibitor DDD00057570 in Trypanosoma cruzi

Oct 2026 · bioRxiv · 0 citations · 3 references
Biology

TL;DR

A compound originally designed to block the same enzyme in the related parasite causing leishmaniasis is found that it blocks the recombinant enzyme, slows the proliferation of the parasite, and reduces the number of parasites bursting from infected mammalian cells, the step by which infection spreads through the body.

Abstract

Background Chagas disease, caused by the parasite Trypanosoma cruzi, affects six to seven million people, and its treatment still relies on two drugs introduced more than fifty years ago, both of limited efficacy and poorly tolerated. The major acidic M17 leucyl-aminopeptidase of T. cruzi is expressed in all developmental stages of the parasite and has been proposed as a drug target, but it has not been pharmacologically validated. Methodology/Principal Findings We assessed DDD00057570, a compound originally identified as an inhibitor of the orthologue enzyme of Leishmania major, against the recombinant T. cruzi enzyme and against the parasite. The compound inhibited the recombinant enzyme with an IC50 of 2.7 ± 0.9 µM and reduced the proliferation of insect-stage epimastigotes, with a half-maximal effective concentration of 3.7 ± 1.1 µM. Parasites engineered to overexpress the enzyme were twice as resistant to the compound as wild-type parasites, indicating that the enzyme is a primary target in the living parasite. Treatment increased the proportion of epimastigotes with fragmented DNA. In infected mammalian cells, the compound reduced the release of trypomastigotes, the stage responsible for dissemination in the mammalian host, with a half-maximal effective concentration of 1.3 ± 0.6 µM, while its half-maximal cytotoxic concentration on CHO-K1 mammalian host cells was 41.5 ± 3.9 µM, resulting in a selectivity index of approximately 32. Conclusions/Significance These results validate the major M17 leucyl-aminopeptidase as a drug target in T. cruzi through target overexpression, and identify DDD00057570 as a selective lead structure warranting mechanistic, pharmacokinetic and in vivo studies toward a new treatment for Chagas disease. AUTHOR SUMMARY Chagas disease is caused by Trypanosoma cruzi, a parasite spread by blood-feeding triatomine insects that affects millions of people, mostly in Latin America. The only two drugs available were discovered more than half a century ago; both often fail and cause side effects severe enough that many patients abandon treatment. New drugs are urgently needed, and finding them starts with knowing which parasite proteins are worth attacking. Herein we studied an enzyme the parasite uses to trim fragments from proteins and release leucine, a building block it needs to proliferate and sustain the infection. We tested a compound originally designed to block the same enzyme in the related parasite causing leishmaniasis. We found that it blocks the recombinant enzyme, slows the proliferation of the parasite, and reduces the number of parasites bursting from infected mammalian cells, the step by which infection spreads through the body. To confirm the enzyme is what the compound attacks, we engineered parasites carrying extra copies of it; these became more resistant, exactly as expected. The compound was far more toxic to the parasite than to mammalian cells. We therefore propose this enzyme as a genuine drug target, and this compound as a starting point.

Read PDF

Similar papers

Open access Oct 2026

In vitro activity of tizoxanide derivatives on Trypanosoma cruzi bloodstream trypomastigotes.

Chagas disease, which is transmitted by Trypanosoma cruzi parasites, remains a major neglected tropical disease for which there are limited treatment choices. In this study, we present the in vitro evaluation of 31 tizoxanide (TIZ) derivatives against the Y strain of T. cruzi bloodstream trypomastigotes. Several of the...

Ana Luiza B. G. Cavalcante, Renata G. Almeida, Joshua Taujanskas et al. · 0 citations
Review Open access Oct 2026

Highlights in Cysteine Protease Inhibitors as Antiparasitic Agents Against Trypanosomatids

Trypanosoma cruzi, Trypanosoma brucei and Leishmania spp. are the causative agents of Chagas disease, human African trypanosomiasis, and leishmaniasis, respectively. These three neglected tropical diseases affect millions of individuals globally, and current therapeutic options remain severely limited. The major cystei...

Beatriz M. R. Querido, M. C. Sousa, J. Salvador · 0 citations
Open access Sep 2026

Integrated Experimental and Computational Investigation of Azobenzenoid Derivatives Against Trypanosomatid: RNA Editing Ligase 1 as a Potential Molecular Target

Interestingly, CaCS2 was a specific ligand to REL1 and non cytotoxic to human cell lines, making it a promising scaffold for anti-trypanosomatid development.

Asif Khan, R. B. Balbinot, Danielle Lazarin-Bidóia et al. · 0 citations
Open access Sep 2026

Highly Selective Thiazole Derivatives as Promising Anti-Toxoplasma gondii Agents

Toxoplasmosis, caused by the protozoan Toxoplasma gondii, remains a significant global health challenge, particularly for immunocompromised individuals. Current therapies, based on pyrimethamine and sulfadiazine, are limited by toxicity, suboptimal efficacy, and the emergence of resistant parasite strains, highlighting...

Ingrid de Oliveira Dias, Gabriel Cândido Moura, Lucas Manoel da Silva Sousa et al. · 0 citations
Open access Sep 2026

Trypanosoma evansi: Molecular Characterization and Validation of a Cathepsin-L-like Peptidase as a Potential Therapeutic Target

TevCATL is validated as a potential therapeutic target for the treatment of animal trypanosomosis caused by T. evansi and treatment with the pan-cathepsin irreversible inhibitor was trypanocidal and significantly increased mice survival.

Adolfo Bremo, Y. G. Pérez, Lilia M. Turcios et al. · 0 citations
Open access Oct 2026

From Enzyme to Parasite: Enzymatic and Phenotypic-Guided Evaluation of Repurposed Inhibitors against Schistosoma mansoni cathepsin D1 ( Sm CD1)

This work evaluated SmCD1 inhibition by a series of 76 acylguanidine compounds obtained through a drug repositioning approach with up to 12-fold selectivity for SmCD1 over the human orthologue.

B. F. Gomes, L. Gomes, R. F. Dantas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.